Substituted Aryl Benzylamines as Potent and Selective Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 3

Screening of Anti-carcinogenic Properties of Phytocompounds from Allium ascalonicum for Treating Breast Cancer Through In Silico and In Vitro Approaches

Plants, rich in phytocompounds, have been in usage since time immemorial for treating various diseases, namely, cancer. One such plant species, Allium ascalonicum (Shallot) belonging to Amaryllidaceae family is being studied here for its anti-carcinogenic properties against breast cancer. GC-MS characterization of A. ascalonicum exhibited 48 phytocompounds containing five peak phytocompounds and 13 phytocompounds with anti-carcinogenic properties. These 13 anti-carcinogenic phytocompounds were docked with three hormonal receptors involved in breast cancer malignancy, namely, ERα, PR, and human EGFR with tamoxifen as standard for in silico analysis. The results exhibited three phytocompounds that had better binding scores compared to that of the standard drug, tamoxifen. Lyophilized powder of aqueous A. ascalonicum extract, also referred as ASE, was used for in vitro approaches. Antioxidant study using DPPH assay revealed that the highest percentage of FRSA in ASE, nearly 51%, was observed at 50 µg/ml concentration. Cytotoxicity study on MCF-7 cell line using MTT assay demonstrated IC₅₀ value at 1400 µg/ml and anti-proliferative study using Trypan blue assay for the determination of percentage viability of MCF-7 cells at IC₅₀ concentration was observed to be 49%. Anti-mitotic activity using Vigna radiata seed germination assay revealed clear morphological differences in a dose-dependent manner between the seeds grown at various concentrations of ASE with nearly 56.5% growth inhibition observed at 1500 µg/ml concentration. Hence, this research work proves that Allium ascalonicum has very good anti-carcinogenic properties and this can be confirmed further through in vivo animal model studies and it can also be formulated as a promising drug to treat breast cancer. GC-MS characterization of Allium ascalonicum demonstrated the presence of five peak compounds and thirteen anti-carcinogenic compounds. The thirteen anti-carcinogenic compounds were docked with three target proteins (in silico analysis) involved in breast cancer malignancy and identified the presence of three potential phytocompounds that can be used for treating breast cancer. In vitro approaches also confirmed the presence of anti-carcinogenic properties such as antioxidative potential, cytotoxic, anti-proliferative, and anti-mitotic effects. Hence, Allium ascalonicum can be taken further to in vivo studies so that it can be formulated to treat breast cancer.